ERBB2 and ductal breast carcinoma in situ: Preoperative assessment of the HER2 status in biopsy-diagnosed pure DCIS could encourage breast surgeons to perform wider local excisions for HER2-positive DCIS, thereby aiming to reduce the risk of involved margins and ipsilateral (in situ) recurrence risk.